HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ECHA Urges Registrants To Weigh Benefits/Risks Of REACH Authorization

This article was originally published in The Rose Sheet

Executive Summary

When all relevant factors are considered, firms may find that it’s not worth pursuing authorization for a substance of very high concern under REACH, European Chemicals Agency rep Richard Dubourg says. In any case, authorization is only temporary until an appropriate alternative presents itself.


Related Content

REACH Authorization Is Working, Says ECHA; Industry Remains Wary
ECHA Should Commit To SVHC Substitution, Not SVHC Manufacturers – EEB
In Brief
EC/REACH Bans Six Substances, Including Musk Xylene And Three Phthalates



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts